Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAITLIN: Adjuvant T-DM1 + Pertuzumab vs Trastuzumab + Pertuzumab + Taxane in HER2+ Breast Cancer
NCT01966471Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2014
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 36
01
Overview
A Phase 3 trial of trastuzumab emtansine in HER2-positive breast cancer, sponsored by Roche. Started Jan 2014; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01966471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01966471.